Garantie de satisfaction à 100% Disponible immédiatement après paiement En ligne et en PDF Tu n'es attaché à rien
logo-home
Samenvatting - Preclinical Drug Research €8,49   Ajouter au panier

Resume

Samenvatting - Preclinical Drug Research

1 vérifier
 125 vues  3 fois vendu

Hoorcolleges PDR: - Pharmaceutical industry - Therapeutic modalities - Drug discovery: choosing the (right)target - Role of medicinal chemistry in drug discovery - Drug discovery process: drug screening technologies - Pharmacokinetics - Pharmacology: role in drug discovery - Patent issue...

[Montrer plus]

Aperçu 4 sur 146  pages

  • 19 octobre 2022
  • 146
  • 2020/2021
  • Resume
Tous les documents sur ce sujet (23)

1  vérifier

review-writer-avatar

Par: nikismets35 • 3 mois de cela

avatar-seller
lizaburdz
Preclinical drug research
Contents
Pharmaceutical industry .................................................................................................................... 1
Therapeutic modalities .................................................................................................................... 11
Drug discovery: choosing the (right)target ....................................................................................... 23
Role of medicinal chemistry in drug discovery ................................................................................. 31
Drug discovery process: drug screening technologies ...................................................................... 36
Pharmacokinetics ............................................................................................................................ 52
Pharmacology: role in drug discovery .............................................................................................. 70
Patent issues in drug discovery ........................................................................................................ 75
Management of drug discovery ....................................................................................................... 76
Drug development: introduction ..................................................................................................... 78
Assessing drug safety....................................................................................................................... 82
Pharmaceutical development ........................................................................................................ 125
Paediatric drug development ........................................................................................................ 138



Pharmaceutical industry

Process of developing a molecule to a drug is very long – can take up to 15 years
- Very risky: high probability of failure
- Drug development = expensive

Drug can have 3 names:
1. Chemical name: used by scientists eg acetylsalicylic acid
2. Generic name: universal name eg aspirin
o When a drug is developed, it is patented
o When the patent expires, other companies can resell the drug for a much cheaper
price = it becomes a generic drug
3. Trade name: registered trademark name eg Sedergine®
→ if another company resells it, they give it a new tradename, even though it remains the
same generic drug



In drug discovery you go from a molecule to a drug.
- Chemicals: small molecules with a certain, simple molecular structure → eg aspirin,
fluoxetine, omeprazole
- Natural products: more complex molecules → eg artemether (for malaria), paclitaxel,
vinblastine
- Biologicals: large (complex) molecules → very variable and quite large group of compounds
eg monoclonal AB (MAB) → eg insulin, EPO, interferon, vaccines, gene therapy,…




1

,1 – 2 billion USD to develop drug:
- 21,5% - preclinical trial
- 56,9% - clinical trials
- 8,3% - approval
- 9,8% - pharmacovigilance

Phases of drug development:
1. Discovery: can be up to 10 years
2. Patent application
3. Preclinical studies: in vitro or in vivo experiment to obtain preliminary
efficacy, toxicity and pharmacokinetic information
4. Clinical:
o Phase I: low doses are given to healthy volunteers designed to test the safety, side
effects, best dose, pharmacokinetics, pharmacodynamics and formulation method
for the drug
▪ 20 – 100 healthy volunteers
▪ Mainly done on male students, because the company doesn’t want to risk
damaging a foetus if a woman was to be pregnant and they don’t want to
interfere with the fertility of women (because in men sperm is made
continuously while female eggs are not)
▪ Often run by contrast research organizations who conduct these studies on
behalf of pharmaceutical companies (outsourced)
o Phase II: trials on patients (vs placebo group) to asses how well the drug works as
well as to continue phase I safety assessments in a larger group
▪ 50 – 300 patients
▪ If possible, companies try to enrol only men (is obviously not always
possible) here as well, but if you want/need women you need to provide
preclinic evidence that it is not teratogenic and that it doesn’t have an effect
on female fertility (so you need to do more preclinical tests)
▪ First indication of the therapeutic potential of the drug
o Phase III: randomized controlled multi-centre trials on large, diverse patient groups
(300–3,000 or more depending upon the disease/medical condition studied) and are
aimed at being the definitive assessment of how effective the drug is, in comparison
with current 'gold standard' treatment
→ most expensive part because there are a lot of doctors, medical personnel,…
involved → if this phase fails, it means that the company loses a lot of money (so its
best to fail in the preclinical trial because then you lose less money)
- Pharmacovigilance: company must follow up on the drug after its on the market to see if it
doesn’t cause any other detrimental effects (because even if you have a population of
100000 during phase III, there can still be undetected effects)




2

,Time for each phase can vary. This
depends on the indication… For each
phase of the clinical development you
need different preclinical packages.
So the sequence: preclinical → clinical
→ market is not correct

Correct is: preclinical – phase I –
preclinical – phase II - …

This course focuses mainly on the
preclinical part before phase I

Patents start before the preclinical
trials and expires after 20 years, so if all
goes well the patent can only be
profitable for about 5 years.

- in the past: when there was a new indication for the drug, the duration of the patent could
be expanded by 5 years, but not it is not possible anymore: all indications must be addressed
from the start
- the timing to take a patent is critical and very difficult
o too early: there is not much time after registration of the drug to earn profits before
the patent expires
o too late: because of espionage, your idea can be stolen



Therapeutic areas




The therapeutic areas that companies spend most R&D costs on are:

1. Neurological: Alzheimer, schizophrenia, depression, epilepsy, Parkinson – high failure rate
(so quite low revenue)
2. Metabolic: cancer, osteoporosis, diabetes, obesity
3. Cardiovascular: atherosclerosis, coronary disease, heart failure (has decreases in the last few
years because there are a lot of options available already)
4. Infectious diseases: viral, bacterial, fungal, (parasitic)

3

, Annual population growth rate
The 60+ and 80+ population has increased loads in all the different
regions. So, we have to deal with diseases linked with age (can be very
lucrative). Problem is that the older population often has to take more
than one drug, so interactions can happen, but again it can be very
lucrative for big pharma → focus on other regions and/or age-related
diseases

The older population spends more on healthcare.
Table: sales in certain area – cardio and CNS are the highest


Blockbuster drugs
- Humira: MAB for juvenile arthritis
- Herceptin: MAB for breast cancer
- Red squares: biologicals – are very important now
- 70% of the industry profits come from 20% of the drugs
marketed
→ driving force behind recent mergers (big pharma are
buying up smaller companies to improve their portfolio).
- Pharmaceutical industry is a core sector for Europe (600 000
employees), but competitiveness is declining.

Challenges for pharmaceutical sales
- Generic drugs: a pharmaceutical drug that contains the same
chemical substance as a drug that was originally protected by chemical patents.
There is a shrinking of market exclusivity and subsequently a drop in earnings.
This means that there is a smaller budget for R&D for new drugs. Generic drugs
are allowed for sale after the patents on the original drugs expire. Because the
active chemical substance is the same, the medical profile of generics is believed
to be equivalent in performance. It has the same active pharmaceutical
ingredient, but it may differ in some characteristics such as manufacturing
process, formulation, taste, packaging. Generics are good for the patient, because they
are cheaper.
- Price containment: a process of judiciously reducing costs in a business or limiting them
to a constant level. When pharmaceutical company want to release their drug to the
market, they need to negotiate with all the countries (the ministers of health) about the
amount they can charge for this drug → there are strict rules about incentives from
pharmaceutical companies for GPs (companies can’t choose what they charge)
- Poor product differentiation: the better the differentiation, the better the sales (eg better
taste, longer half-life, more potency…)
- Increased competition from ‘me-too’ drugs: different pharmaceutical companies focus on
the same indications and the same molecules → many similar drugs on the market
- Parallel importation: In the Single Market parallel traders can buy pharmaceuticals in any
EU/EEA country and then under strictly regulated conditions move medicines to the
destination market, repackage them to comply with national legislation and linguistic needs,
and sell them at a lower price than the standard local price, in competition with that same
identical product sold by the manufacturer or its local licensee. This is possible because
prices of individual drugs vary between Member States.
- Counterfeiting of drugs: fraud; eg people sell fake drugs online – unofficial drugs

4

Les avantages d'acheter des résumés chez Stuvia:

Qualité garantie par les avis des clients

Qualité garantie par les avis des clients

Les clients de Stuvia ont évalués plus de 700 000 résumés. C'est comme ça que vous savez que vous achetez les meilleurs documents.

L’achat facile et rapide

L’achat facile et rapide

Vous pouvez payer rapidement avec iDeal, carte de crédit ou Stuvia-crédit pour les résumés. Il n'y a pas d'adhésion nécessaire.

Focus sur l’essentiel

Focus sur l’essentiel

Vos camarades écrivent eux-mêmes les notes d’étude, c’est pourquoi les documents sont toujours fiables et à jour. Cela garantit que vous arrivez rapidement au coeur du matériel.

Foire aux questions

Qu'est-ce que j'obtiens en achetant ce document ?

Vous obtenez un PDF, disponible immédiatement après votre achat. Le document acheté est accessible à tout moment, n'importe où et indéfiniment via votre profil.

Garantie de remboursement : comment ça marche ?

Notre garantie de satisfaction garantit que vous trouverez toujours un document d'étude qui vous convient. Vous remplissez un formulaire et notre équipe du service client s'occupe du reste.

Auprès de qui est-ce que j'achète ce résumé ?

Stuvia est une place de marché. Alors, vous n'achetez donc pas ce document chez nous, mais auprès du vendeur lizaburdz. Stuvia facilite les paiements au vendeur.

Est-ce que j'aurai un abonnement?

Non, vous n'achetez ce résumé que pour €8,49. Vous n'êtes lié à rien après votre achat.

Peut-on faire confiance à Stuvia ?

4.6 étoiles sur Google & Trustpilot (+1000 avis)

62890 résumés ont été vendus ces 30 derniers jours

Fondée en 2010, la référence pour acheter des résumés depuis déjà 14 ans

Commencez à vendre!
€8,49  3x  vendu
  • (1)
  Ajouter